Darren R. Feldman, Robert J. Motzer, Andrea Knezevic, Martin H. Voss, Serge K. Lyashchenko, Hijin Park, Steven M. Larson, Neeta Pandit-Taskar. "STARLITE 2: Phase 2 study of nivolumab plus
            <sup>177</sup>
            lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (
            <sup>177</sup>
            Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps4612